Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter

Imaging by scintigraphy the serotonin transporter (5-HTT) in the living human brain would be of great value in research on the pathophysiology and treatment of neuropsychiatric disorders such as depression. For that reason, and in order to obtain a selective radiotracer applicable to PET, we report here the carbon-11 labelling of a selective 5-HTT radioligand: N, N-dimethyl-2-(2-amino-4-methylphenylthio)benzylamine or MADAM in two different positions: [p-11C-methyl]MADAM and [N-11C-methyl]MADAM. The synthesis of Bu3Sn-ADAM and N-dimethyl-MADAM is described. [p-11C-methyl]MADAM was obtained by a Stille coupling reaction between Bu3Sn-ADAM and [11C]methyl iodide using palladium (0) as a catalyst without (Ia) or with copper chloride as a co-catalyst (Ib). [N-11C-methyl]MADAM was obtained by an N-methylation reaction between N-demethyl-MADAM and [11C]methyl iodide (II). The carbon-11 incorporation yield in [p-11C-methyl]MADAM was 10–30% (Ia and Ib) and in [N-11C-methyl]MADAM was 75-80% (II). The final product in each case was obtained in 30 min total synthesis time, including HPLC purification and with >99% radiochemical purity. Copyright © 2001 John Wiley & Sons, Ltd.

[1]  M. Kuhar,et al.  [123/125I]RTI‐55, an in vivo label for the serotonin transporter , 1992, Synapse.

[2]  A. Pawlyk,et al.  Altered serotonin transporter sites in Alzheimer's disease raphe and hippocampus. , 1995 .

[3]  Yasuyoshi Watanabe,et al.  Synthesis of a 11C-labelled prostaglandin F2α analogue using an improved method for stille reactions with [11C]methyl iodide , 2000 .

[4]  J. Sandell,et al.  Precursor synthesis and radiolabelling of [11C]ADAM: a potential radioligand for the serotonin transporter exploration by PET , 2001 .

[5]  B. Långström,et al.  Synthesis of 11C/13C-labelled prostacyclins. , 1998, Acta chemica Scandinavica.

[6]  Zsolt Szabo,et al.  Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652 , 1995, Synapse.

[7]  F I Carroll,et al.  High‐affinity binding of [125I]RTI‐55 to dopamine and serotonin transporters in rat brain , 1992, Synapse.

[8]  C. Nemeroff,et al.  Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. , 1994, Clinical chemistry.

[9]  W. Jagust,et al.  In vivo imaging of the 5-hydroxytryptamine reuptake site in primate brain using single photon emission computed tomography and [123I]5-iodo-6-nitroquipazine. , 1993, European journal of pharmacology.

[10]  P. Acton,et al.  2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. , 2000, Nuclear medicine and biology.

[11]  Alan A. Wilson,et al.  Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.

[12]  J. Palacios,et al.  Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: An autoradiographic study with [3H]citalopram , 1993, Neuroscience.

[13]  J. Sandell,et al.  PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter. , 1999, Nuclear medicine and biology.

[14]  H. Schindlbauer.  Reaktionen mit Dimethylformamid, 1. Mitt.: Synthese von Carbonsäuredimethylamiden , 1968 .

[15]  W. Jagust,et al.  Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  J. Karhu,et al.  Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography , 1997, European Journal of Nuclear Medicine.